

# Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study

Andrew Alexis, Marjolein de Bruin-Weller, Stephan Weidinger, Weily Soong, Sebastien Barbarot, Ileana Ionita, Fan Zhang, Hernan Valdez, Claire Clibborn, Natalie Yin


## Changes in EASI in Different Body Regions

EASI Regional Score  
(least squares mean  
% change from baseline)


Median Time to  
EASI-75, days

Week 2


Week 16




Abrocitinib 200 mg QD




Abrocitinib 100 mg QD



Placebo



Dupilumab 300 mg Q2W



1

Head and neck

2

Upper limbs

3

Trunk

4

Lower limbs